Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ: CELG) stock. Someone I knew told me that I probably shouldn't get too excited about the biotech. I'm glad I didn't listen to the person's advice.
Celgene is a much bigger and much more successful company now than it was then. However, there are still some who doubt the biotech's ability to achieve its goals. They question if its pipeline candidates will be as good as Celgene thinks they'll be.
Some of these doubts were raised during a conversation with Celgene CEO Mark Alles at the Morgan Stanley healthcare conference a few days ago. I thought Alles addressed those doubts pretty well. I also think many investors are still underestimating Celgene. Here's why that's a huge mistake.
Source: Fool.com
Johnson & Johnson Aktie
Johnson & Johnson erfreut sich großer Beliebtheit, mit einer hohen Zahl an Buy- und niedriger Zahl an Sell-Einschätzungen.
Das Kursziel von 194 € für Johnson & Johnson impliziert eine deutliche Steigerung um über 20% gegenüber 148.28 €.
